Esperion Therapeutics, Inc. (ESPR) Given Average Rating of “Buy” by Brokerages

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned a consensus rating of “Buy” from the seventeen research firms that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $56.71.

ESPR has been the subject of a number of research analyst reports. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Citigroup Inc. reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Thursday, June 22nd. Jefferies Group LLC initiated coverage on Esperion Therapeutics in a report on Monday, July 10th. They set a “hold” rating and a $55.00 price target for the company. Cowen and Company initiated coverage on Esperion Therapeutics in a report on Thursday, September 7th. They set an “outperform” rating and a $64.00 price target for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $60.00 price target (up from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Lord Abbett & CO. LLC acquired a new stake in Esperion Therapeutics in the 2nd quarter valued at about $6,432,000. Tower Research Capital LLC TRC raised its position in Esperion Therapeutics by 69,371.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 4,856 shares in the last quarter. RA Capital Management LLC raised its position in Esperion Therapeutics by 3.8% in the 2nd quarter. RA Capital Management LLC now owns 731,531 shares of the biopharmaceutical company’s stock valued at $33,855,000 after purchasing an additional 26,830 shares in the last quarter. State Street Corp raised its position in Esperion Therapeutics by 264.6% in the 2nd quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after purchasing an additional 1,093,292 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in Esperion Therapeutics in the 2nd quarter valued at about $1,182,000. 83.30% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://ledgergazette.com/2017/09/24/esperion-therapeutics-inc-espr-given-average-rating-of-buy-by-brokerages.html.

Esperion Therapeutics (ESPR) traded down 0.12% on Friday, reaching $49.31. 412,757 shares of the company’s stock traded hands. The stock’s market capitalization is $1.11 billion. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $57.38. The firm has a 50-day moving average price of $48.34 and a 200-day moving average price of $40.88.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by ($0.25). During the same quarter in the prior year, the firm posted ($0.62) earnings per share. On average, analysts predict that Esperion Therapeutics will post ($7.29) earnings per share for the current year.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply